U.S. markets open in 8 hours 18 minutes

Tetra Bio-Pharma Inc. (TBP.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
0.06500.0000 (0.00%)
At close: 03:50PM EDT
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0650
Bid0.0600 x N/A
Ask0.0650 x N/A
Day's Range0.0600 - 0.0650
52 Week Range0.0500 - 0.3250
Avg. Volume211,980
Market Cap27.519M
Beta (5Y Monthly)1.91
PE Ratio (TTM)N/A
EPS (TTM)-0.1100
Earnings DateJul 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for TBP.TO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • CNW Group

      IIROC Trading Halt - TBP.WT.A

      The following issues have been halted by IIROC:

    • PR Newswire

      Akanda to Supply Tetra Bio-Pharma with Pharmaceutical-Grade Cannabis for FDA Trials of QIXLEEF™, a Potential Multimillion Dollar Prescription Drug

      Akanda Corp. ("Akanda") (NASDAQ: AKAN) and Tetra Bio-Pharma ("Tetra") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), today jointly announced that Akanda will supply Tetra with pharmaceutical grade cannabis flower in a microdose cap form, for use in a Storz & Bickel Mighty Medic Vaporizer for global commercialization of Tetra's QIXLEEFTM and related products. In addition, Akanda will act as a Contract Development and Manufacturing Organization (CDMO) for Tetra's clinical drug and commercial supply progra

    • PR Newswire

      Tetra Bio-Pharma Opens New Subsidiary in Australia and Provides Regulatory Update

      Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development announces the launch of its new wholly owned subsidiary 'Tetra Bio-Pharma Australia Pty Ltd' ("TBP-AU"), an Australian-based research company focused on the execution of clinical trials in Australia. This represents Tetra's second foreign subsidiary and is in line with the Company's global expansion strategy for QIXLEEF™, and other future drug can